Harnessing the power of circular RNA
Circular Genomics is at the forefront of leveraging the potential of circular RNAs to offer personalized diagnoses and treatment options for complex neurological and psychiatric conditions. Circular Genomics’ first product, MindLight™, is a circular RNA-based diagnostic test designed to predict whether a patient with depression will respond to selective serotonin reuptake inhibitors (SSRIs), the most prescribed first-line treatment for depression.
The company is also developing circular RNA blood-based assays for other neurological and psychiatric conditions, including for both the diagnosis and prediction of risk for Alzheimer’s disease.
Our company
Circular Genomics fundamentally transforms patient care by equipping clinicians and informing payers with actionable brain biomarker data. Our cutting-edge, brain-derived circular RNA blood biomarkers provide a real-time view into brain health, empowering personalized treatment decisions that enhance the management of neurological and psychiatric conditions for patients and their families.
